LLY
Eli Lilly and Company
LLY has the edge over PNTG overall, supported by stronger fundamentals and stronger modeled upside.
PNTG
The Pennant Group, Inc.
PNTG offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PNTG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Stable |
PNTG's revenue and profitability are currently healthy, and its cash flow and balance sheet are stable.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PNTG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 24x | $35.91 | — |
| Cheap | 35x | $35.37 | -1.5% |
| Current | 36x | $35.91 | — |
| Fair | 46x | $45.65 | +27% |
| Expensive | 87x | $86.68 | +141% |
Historical ranges are pointers, not guarantees.
PNTG has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over PNTG on the outlook, with more favorable profitability expectations.
PNTG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for PNTG, with profitability holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PNTG on earnings, with stronger typical year-over-year growth.
PNTG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.52 | +52% |
| Q3 2026 | $1.00 | +33% |
| Q2 2026 | $0.91 | +17% |
| Q1 2026 | $0.86 | +13% |
| Q4 2025 | $0.84 | +20% |
| Q3 2025 | $0.75 | +10% |
| Q2 2025 | $0.78 | +24% |
| Q1 2025 | $0.76 | +41% |
| Q4 2024 | $0.70 | +59% |
PNTG's earnings per share have climbed steadily: $1.00 over the past year, up 33% from the year before, and higher year over year for 16 quarters in a row.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PNTG on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PNTG on profitability, with a higher operating margin.
PNTG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $302.3M | +32% |
| Q2 2026 | $298M | +36% |
| Q1 2026 | $285.4M | +36% |
| Q4 2025 | $289.3M | +53% |
| Q3 2025 | $229M | +27% |
| Q2 2025 | $219.5M | +30% |
| Q1 2025 | $209.8M | +34% |
| Q4 2024 | $188.9M | +29% |
PNTG's revenue has grown year over year every quarter since late 2020: $302M last quarter, up 32% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.5% | +1 points |
| Q2 2026 | 5.8% | +0.5 points |
| Q1 2026 | 6.1% | 0 points |
| Q4 2025 | 6% | +1.2 points |
| Q3 2025 | 4.5% | -1.5 points |
| Q2 2025 | 5.3% | -0.4 points |
| Q1 2025 | 6% | +0.6 points |
| Q4 2024 | 4.9% | -0.3 points |
PNTG's operating margin was 5.5% last quarter, up 1 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PNTG on cash flow, with more consistent year-over-year improvement.
PNTG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.1M | -3.2% |
| Q2 2026 | $15.5M | -51% |
| Q1 2026 | -$8.7M | +$14.5M |
| Q4 2025 | $17.4M | +0.9% |
| Q3 2025 | $10.5M | +54% |
| Q2 2025 | $31.6M | +256% |
| Q1 2025 | -$23.2M | -$20.6M |
| Q4 2024 | $17.2M | +511% |
PNTG generated $34M in free cash flow over the past year, down 4.9% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PNTG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PNTG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +427K shares |
| 1 year | +3.2% | +1.1M shares |
| 3 years | +20% | +6.2M shares |
| 5 years | +19% | +5.8M shares |
| Available history | +23% | +6.8M shares |
PNTG has 36M diluted shares, up 3.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q4 2020 | — |
| Q3 2020 | $8,000 |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over PNTG on leverage, with a lower net debt burden relative to earnings.
PNTG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.2x | Moderate |
| Q2 2026 | 2.5x | Moderate |
| Q1 2026 | 2.4x | Moderate |
| Q4 2025 | 2.5x | Moderate |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.4x | Very low |
| Q1 2025 | 1.0x | Very low |
| Q4 2024 | -0.6x | Net Cash |
PNTG's net debt is about 2.2 years of its operating earnings (EBITDA), up from less than a year a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PNTG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.9 | Neutral |
| Stochastic | 27.8 | Neutral |
PNTG's weekly RSI is 45 (neutral) and its Stochastic is 28 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PNTG PE vs Healthcare Sector
| Metric | PNTG | Sector median | Relative |
|---|---|---|---|
| PE | 36x | 26x | 39% above |
| PE % | 18 | 29 | 11 pts below |
PNTG has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PNTG on trend strength, trading above more of its moving averages.
PNTG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.7 | 9.5% below |
| 20 week MA | $39.6 | 9.2% below |
| 50 week MA | $34.7 | 3.6% above |
| 100 week MA | $30.2 | 19% above |
| 200 week MA | $24.5 | 46% above |
PNTG has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 46% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PNTG on returns for 2026, with the stronger performance.
PNTG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.2 | $61.0 | +90% |
| 2021 | $61.0 | $21.9 | -64% |
| 2022 | $21.9 | $9.95 | -55% |
| 2023 | $9.95 | $13.9 | +40% |
| 2024 | $13.9 | $26.6 | +91% |
| 2025 | $26.6 | $29.1 | +9.1% |
| 2026 YTD | $29.1 | $35.9 | +24% |
PNTG has finished higher in four of the last six years, two of them by more than 50%. It's up 24% so far in 2026.